U.S. Site Closures As Takeda Restructures Vaccines Business
This article was originally published in PharmAsia News
A fundamental restructuring of Takeda's vaccines operations will see the closure of three sites in the U.S. as it consolidates operations in this market in the Boston area as part of a revised global network for the unit.
You may also be interested in...
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
A resolution in a long-running patent dispute, expansion of coronavirus vaccine production, drug development trends over the past decade, hematological malignancies in a clinical trial, and the last instalment in the Scrip Asks series all feature in this week's podcast version of Scrip's Five Must-Know Things.
US research-based association says move to annual drug repricing undermines country’s recent efforts to support innovation and again calls for inclusive discussions around broad health system reforms to create funding headroom.